Registration for a live webinar on 'Innovations in antibiotic discovery: combating resistant infections' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
34. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
35. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
36. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
37. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
38. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
39. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
40. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
41. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
42. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
43. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
44. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
46. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
47. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
48. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
49. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
50. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
51. Cow’s milk allergy: the future
- Dr. Carina Venter
-
52. Cow's milk allergy: management
- Dr. Carina Venter
-
53. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
54. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
55. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
56. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
57. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
58. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
59. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
60. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
61. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
62. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
64. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
65. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
66. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
68. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
69. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
70. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
71. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
72. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
73. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
74. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
75. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
76. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
77. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
78. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
79. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
80. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
81. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
82. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
83. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
84. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
85. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
86. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
87. AI and big data in drug discovery
- Mr. Ed Addison
-
88. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
89. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
90. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
91. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
92. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
93. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
94. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
95. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
96. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
97. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
98. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
99. New drugs for asthma
- Prof. Peter Barnes
-
100. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
101. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- What this talk will cover
- What this talk will not cover
- Lifetime chance of getting cancer
- UK cancer statistics
- Paradigm #1
- The beginnings of chemotherapy
- Advances in genomic biology has improved our understanding of cancer
- Understanding cancer pathways
- Early 2000s: targeted therapy era
- Acquired resistance to targeted therapy
- Hallmarks of cancer
- Germline mutations vs. somatic mutations
- Singapore’s Mass Rapid Transport (MRT) map
- Bulk RNA sequencing
- Single cell RNA sequencing
- Spatial profiling
- Components of the TME
- History of immunotherapy evolution
- Steady state of an evolutionary arms race
- Checkpoint blockade
- Paradigm shift #1
- Paradigm #2
- Surgery for cancer therapy
- Surgery to ‘cure’ cancer
- Adjuvant and neoadjuvant therapy
- Total neoadjuvant therapy for rectal cancer
- Paradigm shift #2
- Paradigm #3
- Clinical case 1
- Clinical case 2
- MMR deficient colon cancer – KEYNOTE 177
- 1-, 5- and 10-year survival of most common cancers
- Paradigm shift #3
- Concluding remarks
- Thank you
Topics Covered
- Cancer therapy and the immune system
- Chemotherapy and radiotherapy
- History of cancer treatment
- Advances in cancer therapy
- Acquired resistance to cancer therapy
- Cancer cells hijack cellular pathways
- Targeted cancer therapy
- Sequencing
- Cancer cells and the tumour microenvironment
- Immunotherapy
- Surgery and cancer treatment
- Adjuvant and neoadjuvant therapy
- Total neoadjuvant therapy
- Stage IV cancer
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Sundar, R. (2025, March 31). Harnessing the immune system for cancer therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved May 9, 2025, from https://doi.org/10.69645/JHNS2230.Export Citation (RIS)
Publication History
- Published on March 31, 2025
Financial Disclosures
- Advisory board Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas, Pierre-Fabre, Tavotek, Astra Zeneca, Sanofi, Daichii Sankyo, Beigene Honoraria for talks MSD, Eli Lilly, BMS, Roche, Taiho, Astra Zeneca, DKSH, Ipsen, Daiichi Sankyo, Beigene, Astellas Travel Roche, Astra Zeneca, Taiho, Eisai, DKSH, Ipsen, CytoMed, Paxman Research funding Paxman Coolers, MSD, Natera, CytoMed Patents Paxman, Auristone
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:00
Good day. I'm Raghav Sundar.
I'm an associate professor at
the National University
of Singapore and
also a senior consultant
medical oncologist
at the National University
Cancer Institute of Singapore.
Today, I'll be sharing
with you a topic
titled "Harnessing the Immune
System for Cancer Therapy".
0:22
These are my disclosures.
0:25
Today, I'm going to be
talking to you about some of
the paradigm shifting
changes that
have occurred in oncology
in the past decade.
0:34
However, what I will
not cover today are
the theories about how to treat
and manage individual cancers.
I must say though that as
a gastrointestinal
oncologist specializing in
treating patients with
colon cancer, stomach,
and esophageal cancers,
as well as
hepato-pancreatic-biliary cancers,
a lot of the examples
that I will show
today might lean towards
these tumor types.
But what is more
important to take
note is that these are examples
and proof of principles
of some of the
concepts I'm going to try
and bring about today.
1:10
Many of us know that getting
cancer is very common.
However, what may not be
common knowledge is the
fact that actually,
the lifetime chance
of getting cancer in
men is one in two and for
women is one in three.
This can be potentially
very scary thinking
about half of us as men might
get cancer and a third of us as
women might end up getting
cancer sometime
during our lifetime.
1:38
However, everything is
not all that dismal.
While it is true that
one in two of us
might be diagnosed with
cancer in our lifetimes,
more of us are beating
cancer than ever before.
Survival rate for
cancer patients over
the past 20 or 30 years has
more than doubled
and today, I will be
sharing with you a little bit
about why this is happening.